Adrian Towse

Office of Health Economics

MA, MPhil

12 Whitehall

London, SW1A 2DY

United Kingdom

http://www.ohe.org

SCHOLARLY PAPERS

18

DOWNLOADS
Rank 31,763

SSRN RANKINGS

Top 31,763

in Total Papers Downloads

1,487

SSRN CITATIONS
Rank 22,777

SSRN RANKINGS

Top 22,777

in Total Papers Citations

9

CROSSREF CITATIONS

25

Scholarly Papers (18)

1.

Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents

AEI-Brookings Joint Center Working Paper No. 03-7
Number of pages: 35 Posted: 16 Jul 2003
Patricia M. Danzon and Adrian Towse
University of Pennsylvania - Health Care Systems Department and Office of Health Economics
Downloads 838 (29,111)
Citation 29

Abstract:

Loading...

differential pricing, pharmaceuticals, developing countries, parallel trade, Global Fund

2.

New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options

Number of pages: 52 Posted: 25 Aug 2015
Priya Sharma and Adrian Towse
Office of Health Economics and Office of Health Economics
Downloads 112 (254,316)
Citation 10

Abstract:

Loading...

3.

Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?

Number of pages: 7 Posted: 25 Aug 2015
Martina Garau, Adrian Towse and Patricia M. Danzon
Office of Health Economics, Office of Health Economics and University of Pennsylvania - Health Care Systems Department
Downloads 93 (288,435)
Citation 2

Abstract:

Loading...

4.

Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold

Number of pages: 71 Posted: 25 Aug 2015
Office of Health Economics, Office of Health Economics, Office of Health Economics and RAND Europe
Downloads 86 (302,993)
Citation 8

Abstract:

Loading...

5.

What is the Role of HTA for Biosimilars?

Number of pages: 48 Posted: 25 Aug 2015
Jorge Mestre-Ferrandiz and Adrian Towse
Office of Health Economics and Office of Health Economics
Downloads 69 (344,201)
Citation 1

Abstract:

Loading...

6.

The Market for Biosimilars: Evolution and Policy Options

OHE Briefing, No. 45, October 2008
Number of pages: 24 Posted: 27 Aug 2015
Merck & Co., Inc. - Merck Serono Company, Office of Health Economics and Office of Health Economics
Downloads 55 (385,887)

Abstract:

Loading...

7.

Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context

NBER Working Paper No. w18593
Number of pages: 23 Posted: 07 Dec 2012 Last Revised: 16 Oct 2014
University of Pennsylvania - Health Care Systems Department, Office of Health Economics and Office of Health Economics
Downloads 45 (420,698)

Abstract:

Loading...

8.

Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches

OHE Research Paper 11/04
Number of pages: 32 Posted: 19 Aug 2015
Jon Sussex, Adrian Towse and Nancy Devlin
RAND Europe, Office of Health Economics and Office of Health Economics
Downloads 29 (489,837)
Citation 1

Abstract:

Loading...

9.

International Decision Support Initiative: Mapping of Priority-Setting in Health for 17 Low and Middle Countries Across Asia, Latin America and Africa

Number of pages: 123 Posted: 25 Aug 2015
Office of Health Economics, NICE International, Office of Health Economics and NICE International
Downloads 25 (511,615)
Citation 1

Abstract:

Loading...

10.

Comparative and Relative Effectiveness: A Challenge for Health Systems, Regulators, or Pharmaceutical Companies?

Number of pages: 13 Posted: 23 Aug 2015
Adrian Towse
Office of Health Economics
Downloads 25 (511,615)

Abstract:

Loading...

11.

Incentives for R&D for New Antimicrobial Drugs

OHE Research Paper 11/02
Number of pages: 20 Posted: 19 Aug 2015
Adrian Towse and Priya Sharma
Office of Health Economics and Office of Health Economics
Downloads 22 (529,277)

Abstract:

Loading...

12.

Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement

NBER Working Paper No. w17174
Number of pages: 33 Posted: 05 Jul 2011
University of Pennsylvania - Health Care Systems Department, University of Pennsylvania - The Wharton School and Office of Health Economics
Downloads 21 (535,213)
Citation 2

Abstract:

Loading...

13.

Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?

OHE Research Paper 12/03
Number of pages: 27 Posted: 19 Aug 2015
Office of Health Economics, Office of Health Economics, University of Washington, University of Washington and Novartis Institutes for Biomedical Research - Novartis Pharma AG
Downloads 20 (541,298)
Citation 3

Abstract:

Loading...

14.

Using QALYs in Cancer: A Review of the Methdological Limitations

Number of pages: 28 Posted: 22 Aug 2015
Office of Health Economics, Office of Health Economics, University of York, Independent, Office of Health Economics and University of York - Centre for Health Economics
Downloads 14 (578,435)

Abstract:

Loading...

15.

The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?

Number of pages: 14 Posted: 25 Aug 2015
Adrian Towse, Louis Garrison and Ruth Puig-Peiro
Office of Health Economics, University of Washington and Office of Health Economics
Downloads 13 (584,870)
Citation 1

Abstract:

Loading...

16.

Is the Link between Health and Wealth Considered in Decision Making? Results from a Qualitative Study

Number of pages: 20 Posted: 16 Aug 2015
Office of Health Economics, Office of Health Economics, United States Agency for International Development (USAID) and Office of Health Economics
Downloads 11 (598,124)

Abstract:

Loading...

17.

Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds. Notes on a Conference in Honour of Bernie O’Brien.

OHE Briefing, No. 42, October 2006
Number of pages: 16 Posted: 27 Aug 2015
Adrian Towse and Martin Buxton
Office of Health Economics and Brunel University London - Health Economics Research Group (HERG)
Downloads 9 (611,281)

Abstract:

Loading...

18.

Modelling the R&D Process for Global Diseases Driven By Public-Private Partnersips (PPPs)

iHEA 2007 6th World Congress: Explorations in Health Economics Paper
Posted: 07 Jul 2007
University of Nottingham, Office of Health Economics, Office of Health Economics, Office of Health Economics, University of Oxford - Health Economics Research Centre (HERC) and Office of Health Economics

Abstract:

Loading...

Markov model, R&D process, global diseases

Other Papers (1)

Total Downloads: 0
1.

Donor Investment Choices in Developing Countries: A Methodology and Some Illustrative Results Based on Public-Private Partnerships for Product Development (PD PPPs)

iHEA 2007 6th World Congress: Explorations in Health Economics Paper
Posted: 09 Jun 2007
University of Oxford - Health Economics Research Centre (HERC), University of Nottingham, Office of Health Economics, Office of Health Economics and Office of Health Economics

Abstract:

Loading...

Cost-effectiveness frontiers, R&D process, global diseases, Product Development Public Private Partnerships